Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2017-05-19 Capital/Financing Update
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement used by companies to register securities for public offering, often as a shelf registration allowing multiple offerings up to a certain amount. The document includes details about the types of securities to be offered, the maximum aggregate offering price, and procedural information about the registration and offering process. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a capital markets filing related to fundraising and securities issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement text, not just an announcement or notice, supporting a high confidence level.
2017-05-19 English
FORM 10-Q
Interim / Quarterly Report Q1 2017
2017-05-11 English
FORM DEFR14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'AMENDMENT No. 1 TO OUR PROXY STATEMENT FOR OUR ANNUAL MEETING OF STOCKHOLDERS' and references a definitive Proxy Statement filed with the SEC. It discusses amendments to voting procedures and clarifications related to the proxy statement for the annual meeting. The form type is DEFR14A, which is an amendment to a definitive proxy statement. Proxy statements and their amendments are materials sent to shareholders to provide information and request votes for meetings, fitting the Proxy Solicitation & Information Statement category. The document is not a full annual report, earnings release, or other financial report, but an amendment to proxy materials. Therefore, the correct classification is Proxy Solicitation & Information Statement (PSI).
2017-05-02 English
FORM DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' filing related to a proxy statement. Proxy statements and related materials are classified under 'Proxy Solicitation & Information Statement' (PSI). The document is short (1731 characters) and does not contain financial data or other report content, confirming it is proxy solicitation material rather than a full report or announcement.
2017-04-28 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2017-04-28 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 11, 2017, by BioCardia, Inc. The content focuses on amendments to the company's Articles of Incorporation and Bylaws, including details about the classification of directors, voting requirements, and procedural changes. It includes exhibits of the amended and restated Certificate of Incorporation and Bylaws. There is no financial data or earnings information, nor is it a report of voting results or a proxy solicitation. The document announces changes in corporate governance structure and bylaws, which aligns with Board/Management Information filings. Therefore, the document is best classified as MANG (Board/Management Information). The document length (8196 characters) supports it being a substantive filing rather than a brief announcement or certification.
2017-04-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.